

RECEIVED

JAN 03 2002

TECH CENTER 1600 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1646
)	
Matthew Todd GILLISPIE et al.)	Examiner: D. Jiang
)	
Serial No.: 09/030,061)	Washington, D.C.
)	
Filed: February 25, 1998)	January 4, 2002
)	
For: OSTEOCLASTGENIC...)	Docket No.: GILLISPIE=1

AMENDMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of July 5, 2001,
petition and payment for a three month extension of time being
attached hereto, please amend as follows:

IN THE CLAIMS

Please replace claims 1-3 with new amended claims 1-
3 as follows below. A marked up version of the amended claims
to show the changes made is attached hereto.

1(Twice-amended). An osteoclastgenic inhibitory
composition for treating and/or preventing osteoclast-related
diseases, which comprises a pharmaceutically-acceptable
carrier and, as an active ingredient, an effective amount of
an interleukin-18 comprising the amino acid sequence of SEQ ID